About US
Contact us
-
Bellus Health agrees to sell Thallion to US firm Taro PharmaceuticalsBellus Health has signed an agreement to sell its wholly owned subsidiary Thallion Pharmaceuticals, including all the rights to the Shigamab drug candidate to US-based Taro Pharmaceuticals. Taro will2017/3/23
-
UK NICE Board approves changes to drug evaluation processThe UK National Institute for Health and Care Excellence (NICE) board has approved changes to the drug evaluation process. The introduction of a new fast-track option for appraising treatments, a bud2017/3/22
-
GSK submits application to FDA for expanded indication of influenza vaccineUK's GlaxoSmithKline (GSK) has submitted a supplemental biologics licence application (sBLA) to the US Food and Drug Administration (FDA) for expanded indication of its influenza vaccine, Fluarix Quad2017/3/22
-
FDA grants orphan drug designation to Boehringer Ingelheim’s antibody BI 836858The US Food and Drug Administration (FDA) has granted orphan drug designation to Boehringer Ingelheim’s anti-CD33 monoclonal antibody, BI 836858, which is being investigated in the treatment of myelod2017/3/21
-
FDA grants IND clearance for Servier’s UCART19 to treat relapsed / refractory ALLThe US Food and Drug Administration (FDA) has granted an investigational new drug (IND) clearance to Servier to proceed with the clinical development of UCART19 in the country. UCART19 is an allogene2017/3/21
-
Pharnext and Galapagos partner to generate new pipeline of synergistic drug combinationsFrench biopharmaceutical company Pharnext has announced a research and development (R&D) agreement with Galapagos to generate a new pipeline of synergistic drug combinations. The agreement will i2017/3/20
-
BerGenBio and Merck to evaluate BGB324 with Keytruda in NSCLC and breast cancerNorwegian-based biopharmaceutical company BerGenBio has signed an agreement to clinically evaluate its lead candidate BGB324 with Merck’s Keytruda (pembrolizumab) in patients with advanced non-small-c2017/3/20
-
Ferring Pharmaceuticals acquires Apricus’ ex-US Vitaros assets and rightsApricus Biosciences has completed the sale of its ex-US assets and rights related to Vitaros, a topical erectile dysfunction cream, to Ferring International Center. The sale is pursuant to a definite2017/3/17
-
Trump's tweet causes pharmaceutical company shares to plungeUS President Donald Trump has pledged to introduce a new system that will help decrease the pricing of drugs and increase competition in the pharmaceutical industry. Without disclosing the details of2017/3/17
-
French biotech MedDay acquires Profilomic's health division to enhance research capabilitiesFrench biotechnology company MedDay has acquired the health division of Profilomic to bolster its current metabolomics research platform SPECMET. Financial details of the transaction have not been di2017/3/16